TO ENTER THE GLOBAL MARKET.
Innovation without barrier
1 - 1
WANTED TECHNOLOGIES 2021
ACCESS TO INNOVATION
JTG NEWS & INFO
Wellspring Announces Japan Technology Group as a Channel Partner for Japan Market
Wellspring Worldwide, the leader in software for technology transfer and corporate innovation management, today appointed Japan Technology Group (JTG) as a strategic channel partner in Japan.
Click to see full details...
Contract to research and identify European industrial technologies of high cooperation and business potential for Japan.
Japan Technology Group as member of the International Consortium has been awarded a contract to research and identify European industrial technologies of high cooperation and business potential for Japan. Click to see full details...
JAPAN TECHNOLOGY GROUP, Inc. has signed a MOU with I-DEALS INNOVATION &
TECHNOLOGY VENTURING SERVICES, S.L.U ( everis Group, subsidiary of the NTT Data Group)
What people are saying
“JTG has proven to be very dependable and as advertised, they are extremely well connected to the research community in Japan. Their core expertise and approach to doing business are in alignment with our objectives. As a result, we have been able to establish several strategic relationships and collaboration opportunities.”
University of Hawai‘i
Director Business Development, Office of the Vice President for Research and Innovation
Respond, Apply or Request more info
What is the context of the problem that we would like to solve?
Based on estimations by the World Health Organization, approximately 300 million people
will be obese in 2035. With this, obesity presents a major health concern with increasing
Therapies aiming at regulating food intake currently present the most effective medical
treatment for obesity. However, as reduction of food intake is usually accompanied by
reduced energy expenditure, efficacy of such approaches and in particular the potential for
sustained weight loss is limited. Therefore, combinations with energy expenditure
increasing mechanisms are urgently needed.
Exploiting the full therapeutic potential of energy expenditure mechanisms needs to
incorporate adipose tissue specific mechanisms, as it presents a major tissue regulating
energy metabolism. Pharmacological utilization of therapeutic targets within adipose tissue
ultimately depends on tissue-selective drug delivery. Whereas progress was made in the
past targeting liver via N-acetylgalactosamine (GalNAc)-conjugates and tissue specific cell
surface receptor, no suitable surface proteins were identified that exclusively express in
adipocytes. Based on the urgent need to incorporate energy expenditure mechanisms in
the treatment of obesity, there is a high interest in identifying and characterizing novel
approaches for a cell-type specific targeting of adipose tissue.
What potential solutions could be in scope?
Any unconventional but feasible approach that allows identifying and verifying adipose
tissue-specific molecules for drug-delivery approaches, from biological matrices such as
primary cells, cell lines, organoids, or tissues. Different adipose depots, e.g. white and
brown adipose tissue, are considered equally relevant. The species is not only limited to
humans, however, proposals demonstrating feasibility in human systems are prioritized.
In addition, any already identified adipose-specific molecule or technical approach to
specifically target adipose tissue, not yet public or described in the context of obesity is of
interest, provided that there is a translatability to humans or at least evidence in metabolic
relevant cellular or animal models.
The proposal needs to be highly feasible, should be based on established and existing
methods, assays and involve tools or reagents that are either available or which can be
easily produced. We expect that the project will be executed in your laboratory and takes
advantage of existing technologies and assays.
What potential solutions would be out of scope?
Please note that any proposal ultimately inhibiting adipogenesis or ablating adipose tissue
will not be considered.
Projects that are based on technologies that require first substantial establishment and
validation (no previous hands-on experience) will be deprioritized.
What benefits do we offer to you in exchange for having submitted a solution?
We are open to all proposals that can fully or partially meet its requirements.
If your project is selected, you will have the opportunity to directly collaborate with the
Cardio Metabolic Diseases Research team of Boehringer Ingelheim. You can expect
appropriate funding for the prospective collaboration period. The exact funding request
should be outlined in your proposal. As a framework, we suggest that your initial funding
request is structured in milestones and does not exceed 200,000 euros per submitted
project in total.
The opportunity for a funded stay at Boehringer Ingelheim for technology exchange /
training is potentially available, as is the availability of custom biological tools and
Our collaboration agreement will provide full transparency about each partner’s rights &
obligations (including intellectual property rights). As part of the agreement you will be
encouraged to publish following the collaboration agreement (to be negotiated in good
To maintain the highest degree possible in an open innovation environment, we plan to
announce the winner(s) publicly and feature them on opnMe.com and our social media
channels. We would guide you through this process and as part of it we would kindly ask
for your upfront consent, in case our scientific jury had selected your answer.
What are the key success criteria on which we base our selection for the best answer?
We are seeking research collaboration proposals that contain:
• A well-structured proposal outlining a new and compelling scientific approach.
• Outlining of the technical feasibility, and potentially existing data or previous publications that
support feasibility / experience with outlined technology, based on existing techniques and
• Your exact funding request should be outlined in your proposal based on a well-thoughtthrough
project. The project should be structured in milestones and planned with key decision
points (clear Go/No-Go criteria). The funding request for the initial milestones resulting in a
Go/No-Go decision should not exceed 200,000 euros per submitted project in total.
• Proven track record in the required field of expertise.
• Ability to implement the outlined solution as part of a scientific collaboration project with
Boehringer Ingelheim including access to a laboratory.
We are currently seeking answers for the following scientific challenge: How would you
propose to identify and verify novel approaches to specifically target adipose tissue for
delivery of anti-obesity therapeutics?
All incoming answers accompanied by a collaboration proposal will be evaluated by a
scientific jury, and, upon selection, chosen proposals are pursued through a joint
collaboration with the successful applicants. Initial funding of up to 200,000 euros will be
available for each selected proposal.
or E-mail us at firstname.lastname@example.org.
Please specify which technology need(s) you are responding to.
No cost for submitting a proposal
Benefits of responding through JTG
Contact / Inquiries
Japan Technology Group, Inc.
Japan Technology Group, Inc.
Copyright © 2021 Japan Technology Group. All Rights Reserved.